Webinar Overview

In this webinar, Katherine Crawford, PharmD, BCCP, AACC, and Katherine S. Dodd, DO, FACC, discuss additional and new pharmacological therapies to consider when treating worsening Heart Failure (HF). In particular, they review treatments found to significantly reduce rehospitalizations, such as SGLT2i, ARNI, and ferric carboxymaltose, as well as the newer finerenone and vericiguat.

This webinar is part of the larger Managing HF Across the Spectrum: From Recognizing Symptoms to Implementing Appropriate Treatment online course, supported by Bayer AG.

Key Objectives/Learning Outcomes:

1. Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with HF to determine best practices for care.
2. Distinguish pathophysiologic characteristics of current classifications of phenotypes when diagnosing HF to analyze the best HF risk stratification, prevention, and management strategies.
3. Incorporate GDMT, newer therapies, and interprofessional team strategies into treatment care plans for the management of HF to improve care coordination, communication, and patient outcomes.

Webinar Recording

Webinar Participants

Katherine Crawford, PharmD, BCCP, AACC
Katherine S. Dodd, DO, FACC

Credit Information

No credit is being offered for this webinar.